Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies

Rhea-AI Summary

Cardio Diagnostics Holdings successfully completes employer-sponsored heart disease fair in Kansas, with over 75% employee participation.

Positive

• Positive impact on stock price due to successful completion of heart disease fair and high employee participation.

Negative

• None.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States.

FRSTeam of East Kansas and West Missouri, leaders in restoring and cleaning textiles, electronics, and contents in residential and commercial settings, took a significant step in promoting the well-being of their employees and surrounding communities by hosting an innovative heart disease fair on August 2, 2023. In partnership with ConnectClinic, Cardio Diagnostics was onsite to educate employees, their family members, and the community while providing access to onsite screening services.

Chad Ferguson, CEO of FRSTeam of East Kansas and West Missouri, expressed his enthusiasm for the event, stating, "We are immensely proud to have partnered with Cardio Diagnostics in hosting this groundbreaking heart disease fair. Our employees are the backbone of our company, and their health and well-being are our top priorities. We are taking proactive steps to foster a healthier community by leveraging innovative epigenetic-genetic technologies. This is a shining example of how businesses can contribute positively to society.”

More than 75% of the employees participated in the heart disease fair, and by bringing the heart disease fair onsite during work hours, this innovative approach to health and wellness provided valuable education and screening services to employees and their families while ensuring the employer addressed heart disease effectively.

The success of this event underscores the potential for accelerating heart disease care by Employers by partnering with Cardio Diagnostics to bring heart disease onsite with an employer-sponsored initiative. FRSTeam of East Kansas and West Missouri's decision to host the heart disease fair is part of its ongoing commitment to corporate social responsibility. This initiative reflects the company's dedication to the well-being of its employees and the wider community.

About FRSTeam of East Kansas and West Missouri

FRSTeam of East Kansas and West Missouri specializes in restoring and cleaning textiles, electronics, and contents in residential and commercial settings. The company offers unique solutions to recover garments and textiles damaged by fire, smoke, water, or exposure to mold and other contaminants. Focusing relentlessly on quality and customer satisfaction, the company serves individual and commercial clients. The company is located at 1140 Booth Street, Kansas City, KS 66103, United States. LinkedIn and Facebook.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended June 30, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230818253095/en/

Investors:

Gene Mannheimer

Investor Relations

855-226-9991

investors@cardiodiagnosticsinc.com

Media & Public Relations:

Khullani Abdullahi

pr@cardiodiagnosticsinc.com

Source: Cardio Diagnostics Holdings, Inc